Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result

Abstract:
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention.

Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result

Melbourne, Australia | Posted on February 11th, 2009

These results are encouraging news for women seeking options to protect themselves against HIV infection. With the lack of any demonstration of efficacy with human trials of HIV vaccines, this result provides a real boost to the opportunity for topical microbicides such as VivaGel(R).

Although the result from the completed clinical study is not statistically significant and is insufficient to enable registration, it is an important milestone for the product category. PRO2000 gel was also shown to have a good safety profile, no different from the placebo. These findings are significant for Starpharma, given that the active ingredient in PRO2000 gel is in many respects similar to that of VivaGel(R).

"Given the similarity of the two products, this is excellent news for Starpharma. Importantly, VivaGel(R) has a number of differentiating factors including its activity in HIV, HSV-2 (genital herpes) and all clinically relevant strains of human papillomavirus, and its lack of absorption into the bloodstream," said CEO Dr Jackie Fairley.

The completed study also showed that another candidate microbicide, BufferGel(R), which relies on a fundamentally different mechanism of action, was not effective in reducing the risk of HIV infection.

VivaGel(R) is currently being developed under two INDs for the prevention of HIV and genital herpes and is currently in Phase 2a human trials.

####

About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Ben Rogers
Company Secretary
TEL: +61-3-8532-2702

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Nanomedicine

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Announcements

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE